Market by Product Type, Age Group, Distribution Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report that the cough syrup market in Europe is estimated to progress in value at a CAGR of 3.65% during the forecast years 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The
countries assessed in the region consist of:
•
United Kingdom
•
Germany
•
France
•
Spain
•
Italy
•
Rest of Europe
The aging population in
Europe is on the rise, leading to an increased occurrence of respiratory
illnesses, particularly coughs and colds. This has led to a greater need for
cough syrup as older individuals seek efficient solutions to alleviate their
respiratory issues. Additionally, the presence of alternative treatment options
like tablets, lozenges, and herbal remedies may influence consumer preferences
away from the conventional cough syrups.
Germany
dominates the region’s market with the highest share.
The growing preference for over-the-counter (OTC) medications in Germany is
primarily driven by the ease of access and convenience they offer. Cough
syrups, for instance, can be readily found in both pharmacies and retail
stores, eliminating the need for a doctor’s prescription. Additionally, as
Germans increasingly prioritize their well-being and seek milder alternatives,
herbal cough syrups have gained traction, further fueling the cough syrup
market’s growth across the nation.
Similarly, over-the-counter
cough syrups, readily accessible without a prescription, have garnered traction
among individuals seeking respite from coughs and associated ailments in the UK.
Their appeal is significantly boosted by the ease of acquisition through local
pharmacies and retail establishments. Furthermore, the diverse selection of
non-prescription cough and cold remedies within the UK often encompasses cough
syrups designed to address distinct symptoms, be it dry or chesty coughs,
thereby opening avenues for the studied market.
Retail pharmacies offer
a diverse array of cough syrups, providing consumers with a range of choices to
address their specific needs. They typically stock both prescription and
over-the-counter (OTC) cough syrups. Besides, they are strategically positioned
in neighborhoods and commercial hubs, ensuring easy accessibility for
consumers.
The
market is segmented into distribution channel, age group, and product type.
The distribution channel includes retail, hospital, and e-pharmacies.
The
major firms in the market include Cipla Limited, Acella Pharmaceuticals LLC, Sanofi
SA, AstraZeneca Plc, Kenvue Inc, and The Himalaya Wellness Company.
Sanofi is involved in researching, developing, manufacturing, and promoting pharmaceutical products, primarily in the prescription sector. Additionally, the company creates over-the-counter medications. Sanofi’s focus encompasses seven key therapeutic domains: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. The company operates actively in over 135 countries, with headquarters located in Paris, France.
Key
deliverables of the report:
· Market CAGR during the forecasting
years 2023-2030
· Detailed data highlighting key
insights, industry components, and market strategies
· Comprehensive information and
estimation of the cough syrup market revenue growth in Europe and its influence
on the parent market
· In-depth study of forthcoming trends
in consumer behavioral patterns
· A meticulous analysis of the
competitive landscape, vendor scorecard, and Porter’s Five Forces
· A wide-ranging study of factors that
will challenge the Europe cough syrup market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
COUGH SYRUP MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
ANALYSIS ON THE COUGH SYRUP MARKET
2.1.1. COVID-19
IMPACT
2.1.2. UKRAINE-RUSSIA
WAR IMPACT
2.2. PORTER’S
FIVE FORCES ANALYSIS
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. THREAT
OF COMPETITIVE RIVALRY
2.3. INDUSTRY
COMPONENTS
2.3.1. RAW
MATERIALS
2.3.2. MANUFACTURERS
2.3.3. DISTRIBUTORS
2.3.4. RETAILERS
2.4. REGULATORY
FRAMEWORK
2.5. KEY
MARKET STRATEGIES
2.5.1. COLLABORATIONS
2.5.2. PRODUCT
LAUNCHES
2.5.3. ACQUISITIONS
2.5.4. BUSINESS
DIVESTITURES & EXPANSIONS
2.6. MARKET
DRIVERS
2.6.1. HIGH INCIDENCE OF
RESPIRATORY AILMENTS
2.6.2. VULNERABILITY
TO RESPIRATORY DISEASES AMONG THE GERIATRIC POPULATION
2.6.3. INNOVATIONS
IN COUGH SYRUPS
2.7. MARKET
CHALLENGES
2.7.1. OVERDOSE
RISKS ASSOCIATED WITH COUGH SYRUPS
2.7.2. STRICT
REGULATORY REQUIREMENTS
2.7.3. INCREASING
COUGH SYRUP DEATHS DUE TO TOXIC INGREDIENTS
2.8. MARKET
OPPORTUNITIES
2.8.1. SELF-MEDICATION TRENDS
INCREASE DEMAND FOR OTC DRUGS
2.8.2. HERBAL
COUGH SYRUPS EMERGE AS A SAFER ALTERNATIVE
2.8.3. EASE
OF PURCHASE OFFERED BY E-COMMERCE CHANNELS
2.8.4. AVAILABILITY
OF SUGAR-FREE COUGH SYRUPS
2.8.5. GROWING
PREFERENCE FOR HOMEOPATHIC COUGH SYRUPS
2.9. ANALYST
PERSPECTIVE
3. EUROPE
COUGH SYRUP MARKET – BY PRODUCT TYPE
3.1. COUGH
SUPPRESSANTS
3.2. COMBINATION
MEDICINES
3.3. EXPECTORANTS
4. EUROPE
COUGH SYRUP MARKET – BY AGE GROUP
4.1. ADULTS
4.2. ADOLESCENTS
4.3. PEDIATRIC
5. EUROPE
COUGH SYRUP MARKET – BY DISTRIBUTION CHANNEL
5.1. RETAIL
PHARMACIES
5.2. HOSPITAL
PHARMACIES
5.3. E-PHARMACIES
6. EUROPE
COUGH SYRUP MARKET – BY COUNTRY OUTLOOK
6.1. UNITED
KINGDOM
6.1.1. UNITED
KINGDOM COUGH SYRUP MARKET FORECAST & PROSPECTS
6.2. GERMANY
6.2.1. GERMANY
COUGH SYRUP MARKET FORECAST & PROSPECTS
6.3. FRANCE
6.3.1. FRANCE
COUGH SYRUP MARKET FORECAST & PROSPECTS
6.4. ITALY
6.4.1. ITALY
COUGH SYRUP MARKET FORECAST & PROSPECTS
6.5. SPAIN
6.5.1. SPAIN
COUGH SYRUP MARKET FORECAST & PROSPECTS
6.6. REST
OF EUROPE
6.6.1. REST
OF EUROPE COUGH SYRUP MARKET FORECAST & PROSPECTS
7. COMPETITIVE
LANDSCAPE
7.1. GSK
PLC
7.1.1. OVERVIEW
7.1.2. PRODUCT
PORTFOLIO
7.1.3. KEY
STRENGTHS
7.1.4. KEY
CHALLENGES
7.2. PFIZER
INC
7.2.1. OVERVIEW
7.2.2. PRODUCT
PORTFOLIO
7.2.3. KEY
STRENGTHS
7.2.4. KEY
CHALLENGES
7.3. NOVARTIS
AG
7.3.1. OVERVIEW
7.3.2. PRODUCT
PORTFOLIO
7.3.3. KEY
STRENGTHS
7.3.4. KEY
CHALLENGES
7.4. RECKITT
BENCKISER GROUP PLC
7.4.1. OVERVIEW
7.4.2. PRODUCT
PORTFOLIO
7.4.3. KEY
STRENGTHS
7.4.4. KEY
CHALLENGES
7.5. THE PROCTER
& GAMBLE COMPANY
7.5.1. OVERVIEW
7.5.2. PRODUCT
PORTFOLIO
7.5.3. KEY STRENGTHS
7.5.4. KEY
CHALLENGES
7.6. SANOFI
SA
7.6.1. OVERVIEW
7.6.2. PRODUCT
PORTFOLIO
7.6.3. KEY
STRENGTHS
7.6.4. KEY
CHALLENGES
7.7. CIPLA LIMITED
7.7.1. OVERVIEW
7.7.2. PRODUCT
PORTFOLIO
7.7.3. KEY
STRENGTHS
7.7.4. KEY
CHALLENGES
7.8. KENVUE
INC
7.8.1. OVERVIEW
7.8.2. PRODUCT
PORTFOLIO
7.8.3. KEY
STRENGTHS
7.8.4. KEY
CHALLENGES
7.9. ASTRAZENECA
PLC
7.9.1. OVERVIEW
7.9.2. PRODUCT
PORTFOLIO
7.9.3. KEY
STRENGTHS
7.9.4. KEY
CHALLENGES
7.10. ACELLA
PHARMACEUTICALS
7.10.1. OVERVIEW
7.10.2. PRODUCT
PORTFOLIO
7.10.3. KEY
STRENGTHS
7.10.4. KEY
CHALLENGES
7.11. THE
HIMALAYA WELLNESS COMPANY
7.11.1. OVERVIEW
7.11.2. PRODUCT
PORTFOLIO
7.11.3. KEY
STRENGTHS
7.11.4. KEY
CHALLENGES
7.12. MERCK
KGAA
7.12.1. OVERVIEW
7.12.2. PRODUCT
PORTFOLIO
7.12.3. KEY STRENGTHS
7.12.4. KEY
CHALLENGES
7.13. ABBOTT
LABORATORIES
7.13.1. OVERVIEW
7.13.2. PRODUCT
PORTFOLIO
7.13.3. KEY
STRENGTHS
7.13.4. KEY
CHALLENGES
7.14. GLENMARK
PHARMACEUTICALS LIMITED
7.14.1. OVERVIEW
7.14.2. PRODUCT
PORTFOLIO
7.14.3. KEY
STRENGTHS
7.14.4. KEY
CHALLENGES
7.15. DABUR
INDIA LTD
7.15.1. OVERVIEW
7.15.2. PRODUCT
PORTFOLIO
7.15.3. KEY
STRENGTHS
7.15.4. KEY CHALLENGES
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.2. SOURCES
OF DATA
8.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE COUGH SYRUP
MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT
LAUNCHES
TABLE 5: LIST OF ACQUISITIONS
TABLE 6: LIST OF BUSINESS
DIVESTITURES & EXPANSIONS
TABLE 7: EUROPE COUGH SYRUP
MARKET, BY PRODUCT TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: EUROPE COUGH SYRUP
MARKET, BY AGE GROUP, 2023-2030 (IN $ MILLION)
TABLE 9: EUROPE COUGH SYRUP
MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (IN $ MILLION)
TABLE 10: EUROPE
COUGH SYRUP MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
FIGURE 1: INDUSTRY COMPONENTS
FIGURE 2: EUROPE COUGH SYRUP
MARKET, BY PRODUCT TYPE, 2022 & 2030 (IN %)
FIGURE 3: EUROPE COUGH SYRUP
MARKET, BY COUGH SUPPRESSANTS, 2023-2030 (IN $ MILLION)
FIGURE 4: EUROPE COUGH SYRUP
MARKET, BY COMBINATION MEDICINES, 2023-2030 (IN $ MILLION)
FIGURE 5: EUROPE COUGH SYRUP
MARKET, BY AGE GROUP, 2022 & 2030 (IN %)
FIGURE 6: EUROPE COUGH SYRUP
MARKET, BY ADULTS, 2023-2030 (IN $ MILLION)
FIGURE 7: EUROPE COUGH SYRUP
MARKET, BY ADOLESCENTS, 2023-2030 (IN $ MILLION)
FIGURE 8: EUROPE COUGH SYRUP
MARKET, BY PEDIATRIC, 2023-2030 (IN $ MILLION)
FIGURE 9: EUROPE COUGH SYRUP
MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2030 (IN %)
FIGURE 10: EUROPE COUGH SYRUP
MARKET, BY RETAIL PHARMACIES, 2023-2030 (IN $ MILLION)
FIGURE 11: EUROPE COUGH SYRUP
MARKET, BY HOSPITAL PHARMACIES, 2023-2030 (IN $ MILLION)
FIGURE 12: EUROPE COUGH SYRUP
MARKET, BY E-PHARMACIES, 2023-2030 (IN $ MILLION)
FIGURE 13: EUROPE COUGH SYRUP
MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 14: UNITED KINGDOM
COUGH SYRUP MARKET 2023-2030 (IN $ MILLION)
FIGURE 15: GERMANY COUGH SYRUP
MARKET 2023-2030 (IN $ MILLION)
FIGURE 16: FRANCE COUGH SYRUP
MARKET 2023-2030 (IN $ MILLION)
FIGURE 17: ITALY COUGH SYRUP
MARKET 2023-2030 (IN $ MILLION)
FIGURE 18: SPAIN COUGH SYRUP
MARKET 2023-2030 (IN $ MILLION)
FIGURE 19: REST OF EUROPE
COUGH SYRUP MARKET 2023-2030 (IN $ MILLION)